Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you!

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a new [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

Eisai goes to FDA for subcutaneous Alzheimer’s med
Antibody, Alzheimer’s - Read more

BD and Roche both receive FDA approval for at-home vaginal sample collection
Diagnostic devices, HPV, cervical cancer - Read more

Takeda’s Dengue vaccine get’s WHO preapproval
Dengue vaccine, neglected tropical disease - Read more

THE GOOD
Company Launches

Uniquity Bio has a big ol’ $300M launch (and a Ph2 candidate ready to go)
Monoclonal antibody, asthma, COPD - Read more

THE GOOD
Earnings & Finances

Eisai is mega-bullish (think 13-fold growth) on Leqembi sales
Antibody, Alzheimer’s - Read more [Paywall]

THE GOOD
Fundraises

Elegen $35M Series B
DNA Synthesis - Read more

SmarterDx $50M Series B
AI, clinical documentation - Read more

A “Herculean” effort lands Adaptimmune $125M in debt financing
Cell therapy, cancer - Read more

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

THE GOOD
Investments

Novo Holdings has single use on the brain, buys 60% stake in Single Use Support
Sterile manufacturing, single use - Read more

THE GOOD
Lawsuits

Eli Lilly settles with GLP-1 scamming medical spa
GLP-1, obesity - Read more

THE GOOD
Markets Reports

Merck & Co. tops oncologists’ nice lists…but not by much
Cancer, physician opinions - Read more

THE GOOD
Partnerships

Beigene wants more partners, or someone to out-license to
Antibody, cancer - Read more [Paywall]

THE GOOD
Research

Semaglutide cardiac benefits go beyond just weight loss
GLP-1, obesity, cardiovascular health - Read more

THE GOOD
Strategic Plans

Alphabet company Verily’s narrowed focus; interview
Medical device, precision in medicine - Read more

THE BAD
Earnings & Finances

Merck KGaA’s CDMO division continues not having a good time
Sales: €157M ($170M) Q1 2024, down 28.6% from Q4 2024 €220M ($238M)
CDMO, biologics - Read more

Citing “abusive relationship”, Vaxxinity goes private
Peptides, Alzheimer’s, Parkinson’s - Read more

THE BAD
Layoffs

BioMarin to layoff 170 workers - Read more

2 for 1 layoffs; Bolt Bio (50% reduction) and Tenaya Therapeutics (22% reduction)
Antibody conjugate, gene therapy - Read more

THE UGLY
Approvals & Labels

ICER has serious doubts about Lykos’ PTSD trials (misconduct?)
MDMA, psychedelics, PTSD - Read more

THE UGLY
Politics & Policy

US government skyrockets tariffs on Chinese medical supplies (eg. 0% to 50% on syringes and needles)
Tariffs, protectionism - Read more

Biosecure Act advances with bipartisan support
USA-China biopharma, Biosecure Act - Read more [Paywall]

Amgen draws US senator’s ire over alleged “profits over patient[s]”
Small molecule, lung cancer - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍